Understanding Alzheimer's Treatment Studies: A 2026 Guide

Two years ago, confirming amyloid pathology meant either a lumbar puncture or a PET scan costing several thousand dollars out of pocket — and for many families, that cost ended the conversation before it started. Today, high-sensitivity plasma p-tau217 assays — a routine blood draw — can confirm amyloid status with roughly 90% accuracy in hands of validated clinical labs. That single change has transformed how Alzheimer's trial enrollment actually works. Families who call a research site move from "interested" to "formally screened" in weeks, not months. More of them qualify, and fewer of them face the logistical cliff edge that used to stop enrollment cold. If you're exploring trial participation in 2026, understanding that this shift happened — and what it means for the sequence of steps ahead of you — is the right place to start.

Why the Field Finally Moved to Disease Modification — and What That Actually Proved

For decades, Alzheimer's trials tested symptomatic agents — acetylcholinesterase inhibitors, memantine, various combinations. They worked modestly and temporarily. The theoretical case for disease modification was always compelling: if amyloid plaques and tau tangles are the cause, remove them before the neurons they're destroying are gone. But executing that idea took 30 years of failed trials and roughly $40 billion in industry investment before lecanemab's CLARITY-AD data changed the field's calculus.

CLARITY-AD (NCT03887455) enrolled 1,795 participants with early Alzheimer's disease — confirmed by amyloid PET or CSF biomarkers — and showed lecanemab reduced the CDR-SB by 27% relative to placebo over 18 months. The FDA granted traditional approval in July 2023. Donanemab followed with TRAILBLAZER-ALZ 2 (NCT04437511): 35% slowing on the iADRS composite in participants with low-to-medium tau burden, and notably, the highest-activity amyloid clearance of any antibody studied to date — 76% of participants reached amyloid negativity on PET by 12 months. Both approvals came with important caveats. The absolute clinical differences are modest. Neither drug halts progression. But both demonstrated that the biology is tractable, and that confirmation: that proof of concept is what unlocked the current generation of trials.

Current Phase 3 programs are asking what comes next. Can better amyloid clearance, faster clearance, or combination approaches targeting amyloid plus tau produce bigger effects? And critically — does starting treatment before any symptoms appear at all produce the most durable outcomes? That last question drives the entire prevention trial architecture.

The Screening Cascade: What to Actually Expect

This is where practical mechanics matter most. Alzheimer's trial screening in 2026 is a multi-stage process, and knowing the sequence prevents wasted time for everyone involved.

• Plasma p-tau217 or p-tau181 blood test: For most trials, this is now the first biomarker gate. A positive result — elevated p-tau217 — predicts amyloid positivity on PET with roughly 87–90% accuracy in validated assays from Quest or Fujirebio. It doesn't fully replace imaging, but it does serve as a rapid triage that spares many patients the time and cost of PET scans they'd fail anyway.
• Amyloid PET or CSF confirmation: Most interventional trials still require confirmatory PET imaging before enrollment. Some protocols accept CSF Aβ42/40 ratio as an alternative. Crucially, PET scans are typically provided at no cost by the trial sponsor — this is one of the most tangible direct benefits of participation, since out-of-pocket amyloid PET can exceed $5,000 in clinical settings.
• APOE-ε4 genotyping: Every amyloid-targeting antibody trial genotypes participants. Homozygous ε4 carriers face a 3–4x higher rate of ARIA-E than non-carriers. Some trials dose-escalate differently in ε4 homozygotes; others cap their enrollment at a defined percentage of homozygotes to preserve the trial's safety profile. This is disclosed in informed consent and affects dosing decisions — not necessarily your eligibility to participate.
• Cognitive and functional assessments: The MMSE, CDR, and ADAS-Cog are standard. Prevention trials enrolling cognitively normal adults use more sensitive composite measures — such as the Alzheimer's Prevention Initiative Composite Cognitive test (APCC) — specifically designed to detect early change before clinical decline is visible.
• Baseline MRI: All antibody trials require baseline MRI to identify pre-existing microhemorrhages or superficial siderosis that would preclude safe treatment. This is a safety screen, not just a formality.

The Study Partner Requirement — More Consequential Than Most Families Expect

Every Alzheimer's trial requires a designated Study Partner, and this disqualifies more families than any biomarker criterion. The Study Partner must spend at least 10 hours per week with the participant, attend every clinical visit, and independently complete observer-rated assessments of daily functioning. This isn't bureaucratic box-checking. It's structural.

Here's why: the primary endpoints of most disease-modification trials include functional outcomes — the CDR-SB, the ADCS-ADL, the iADRS — that require informant report, not just patient self-report. A participant who lives alone, or whose spouse is also cognitively impaired, may be biomarker-positive and clinically eligible on every other dimension but still cannot enroll. This is worth clarifying at the first phone call with a research site, before investing any time in the biomarker screening cascade. Save yourself and the site team a trip.

• Who qualifies: A spouse, adult child, sibling, close friend, or consistent paid caregiver who has regular contact and can reliably report behavioral and functional changes. The definition is practical, not legalistic — what matters is reliability and availability.
• Caregiver burden instruments: Many trials now include the Zarit Burden Interview or NPI-Q as secondary endpoints or safety measures. Retention of the participant-partner dyad over long study periods is a recognized operational challenge, and trial teams generally have experience supporting partners through it.
• Compensation: Study partners receive reimbursement for travel and time at clinical visits even though they're not the enrolled participant. In long trials with frequent visits, this can represent meaningful financial support.

Study Types and Compensation Overview

ARIA: The Safety Signal That Shapes Every Amyloid Trial

ARIA — Amyloid-Related Imaging Abnormalities — is the dominant safety consideration in every amyloid-clearing antibody program. Understanding it correctly matters when weighing trial participation, because the way it's often described creates either too much alarm or too much reassurance. ARIA comes in two forms: ARIA-E (brain edema visible on FLAIR MRI) and ARIA-H (hemosiderin deposits, microhemorrhages on GRE/SWI). In CLARITY-AD, ARIA occurred in about 21% of treated participants versus 9% on placebo. Most events were asymptomatic — detected only on protocol surveillance MRIs. Symptomatic ARIA occurred in roughly 3% of treated participants.

The management protocol in current trials is protocol-specific but follows a general pattern:

• MRI monitoring every 4–8 weeks during the initial dosing phase, then quarterly — the schedule is intensive, and the MRI costs alone can reach $15,000–$30,000 over a 24-month study, all provided free
• Pre-specified dose hold or discontinuation criteria by ARIA grade: asymptomatic Grade 1–2 typically allows a dose hold with re-escalation; symptomatic or severe ARIA leads to permanent discontinuation
• APOE-ε4 homozygotes face approximately 33–40% ARIA rates versus ~10% in non-carriers — a risk-benefit conversation that belongs in informed consent, handled explicitly, not buried in supplemental data

The real-world implication: the monitoring is intensive, but it's a reason trials provide it free. You're getting quarterly neuroimaging at sponsor cost as a standard part of the protocol. That has standalone clinical value even for participants who never develop ARIA.

Finding the Right Trial — and What the Process Actually Looks Like

The Alzheimer's Association TrialMatch (alz.org/trialmatch) and ClinicalTrials.gov remain the starting points. For prevention trials — enrolling cognitively normal adults at elevated biological risk — the A4 Study established the model: blood biomarker screen first, confirmatory PET if positive. The A45 trial (NCT04468659), testing solanezumab in amyloid-positive cognitively unimpaired adults, follows this model. Several active prevention platforms are running concurrently as of 2026, targeting the pre-symptomatic window that we now have the biomarker tools to actually identify.

One practical thing worth knowing: most major Alzheimer's research centers now have dedicated clinical trial navigators. A 30-minute call with a navigator at an academic memory center can tell you which currently-enrolling trials you might realistically qualify for, what biomarker tests you'd need, and whether your Study Partner situation is workable. That call is free. It saves time. And it's a far more efficient first step than trying to decode protocol eligibility language on your own at 11pm on ClinicalTrials.gov.

Frequently Asked Questions